Written by Jim Hughes

Updated five year adjuvant Gleevec trial: Phase II now open at 21 sites in the United States. NCT00867113

Updated MP470 trial in solid malignancies: Phase I updated to Ongoing as of 11/3/2009. NCT00894894

Added GDC-0980 trial in solid tumors: This Phase I trial of a combined PI3K & mTOR inhibitor is open at Dana-Farber Cancer Center (DFCI), Boston, Mass., Vanderbilt University, Nashville, Tenn. and in Sutton, Surrey, United Kingdom. NCT00854152

Added GDC-0980 trial: This Phase I trial of a combined PI3K & mTOR inhibitor is recruiting at DFCI, Ville Juif, France and Manchester, United Kingdom. NCT00854126

Added PLX108-01 trial: Phase I study is recruiting in Scottsdale, Ariz. and Spokane, Wash. The drug is also called PLX3397. It is a combined fms KIT and Flt3 inhibitor NCT01004861

Added Gleevec trial: This Phase III study of dose escalation versus no dose escalation in metastatic GIST patients is sponsored by the Sarcoma Alliance for Research through Collaboration NCT01004861. It is now recruiting at Sarcoma Oncology Center in Santa Monica, Calif. NCT01031628.

Added STA-9090 trial: This Phase II trial of a second generation small molecule HSP-90 inhibitor is now recruiting at Dana Farber Boston, MA NCT01039519

Added Sutent trial: This phase II trial evaluating patients with bulky GIST is now recruiting at University of Alabama. This trial administers neoadjuvant Sutent prior to prospective surgery at 14-16 weeks after trial entry. NCT01054911

Solely International

Updated Sutent trial: This phase 4 trial in China has changed to ongoing and is no longer recruiting patients. NCT00793871